• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Italfarmaco, Luye enter commercialization pact for transdermal Alzheimer’s treatment

March 16, 2021 By Sean Whooley

Italfarmaco Luye PharmaItalfarmaco Group and Luye Pharma announced today that they entered into a commercialization agreement for Rivastigmine MD.

Under the agreement, Milan, Italy-based Italfarmco receives exclusive rights to commercialize the Rivastigmine multi-day transdermal patch in four European companies, according to a news release.

Italfarmaco gains the rights to commercialize in Germany, Italy, Portugal and Greece under the agreement, while it will also have a preferred right to market Rivastigmine MD in Chile and Vietnam. The company will make an upfront payment to Luye Pharma upon signing,  with additional milestone payments and potential royalties.

Basel, Switzerland-based Luye Pharma developed the Rivastigmine MD to treat mild to moderate dementia associated with Alzheimer’s disease.

Rivastigmine MD is a twice-weekly transdermal patch formulation of the treatment which can improve cognitive functions such as memory and thinking by increasing the amount of a natural substance in the brain and amplifying the communication channels between nerve cells. The drug is currently available in tablet and patch form.

The patch has a lower application frequency than the once-daily patches generally available in the market, offering improvements to medication adherence. The transdermal route of delivery is designed for patients who have difficulty swallowing, while it may have the potential to lower the incidence of gastrointestinal adverse reactions to an oral form.

Rivastigmine MD will be registered in major global markets, including Europe, Japan and China, the companies said, as it has been accepted for review by the European Union and was previously approved for clinical trials in China. Additionally, earlier this year, Luye granted exclusive development and commercialization rights in Japan to Towa Pharmaceutical. Luye also plans to register the device in the U.S., among other countries.

“Alzheimer’s is a debilitating disease with a growing patient population and very few treatment options, so we welcome our partnership with Luye Pharma and the addition of an easy-to-administer, innovative product for patients,” Italfarmaco VP of business & portfolio development Antonio Nardi said in the news release. “In addition to our own research expertise, we are looking forward to building our neurology-focused commercial pipeline in this therapeutic area to provide more options for clinicians who are at the frontline of treating individuals with neurodegenerative diseases.”

“The collaboration with Italfarmaco represents an important milestone in our commitment to addressing unmet needs for senior patients in Europe. By leveraging Italfarmaco’s extensive CNS experience and strong business operation system, we believe we will soon be able to bring this new therapy to patients in Europe,” Luye GM Bruno Delie added. “We aim to improve the quality of life for people suffering from dementia, as well as their families, friends and caregivers.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals Tagged With: Italfarmaco, Luye Pharma

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS